ArticleDiscover oncology2025
Causal links and immune mediators between blood cells and breast cancer risk: a mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have indicated a potential association between blood cells and breast cancer risk, but the causal relationships involving specific blood cell metrics and the role of immune cell mediators remain unclear. This study employs Mendelian randomization to explore the causal relationships between diverse blood cell profiles and breast cancer risk, while also seeking to identify potential mediating factors within immune cell metrics.
methodsWe utilized Mendelian randomization to explore the causal effects of 91 different blood cell types on breast cancer risk, using genetic variants as instrumental variables. The analysis employed the inverse-variance weighted (GWAS) method, with a significance threshold of 0.05, to evaluate the causal relationships. Multivariate analysis was conducted to determine the mediating effects of immune cells in the association between blood cells and breast cancer. Heterogeneity test and multi-small size test are performed to complete the sensitivity analysis, ensuring the stability and reliability of the results.
resultsWe identified significant causal relationships between blood cells and breast cancer risk. Specifically, the Neutrophil perturbation response (the ratio of neutrophil 2 to neutrophil 4 in response to KCl perturbation measured by WDF dye) was found to be causally associated with breast cancer risk. Furthermore, CD45RA-CD4+T cell Absolute Count was identified as a mediator in this relationship. The mediating effect of CD45RA-CD4+T cell Absolute Count was - 0.055 (P = 0.022), indicating that the impact of Neutrophil perturbation response on breast cancer risk is mediated through CD45RA-CD4+T cell Absolute Count.
conclusionOur study highlights a causal relationship between Neutrophil perturbation response and breast cancer risk, with CD45RA-CD4+T cell Absolute Count acting as a significant mediator. These findings provide new insights into the role of immune cells in the relationship between blood cell metrics and breast cancer risk, suggesting potential targets for further research and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.